News

TargetRx, through its AdvantageBuilder database of more than 300 million questions answered by over 80,000 physicians, has identified 11 attributes, or Y-Factors, that motivate physicians to prescribe. The

With this partnership, LSK can implement and support Medidata Rave across all trial phases, sizes and locations and offer sponsors and investigators the ability to reduce delays and

ANVISA provides regulatory approval for drugs and other products seeking to enter the large and growing Brazilian market. In addition to ANVISA certification, Celerion’s Belfast facility has also

ICT-107 is the company’s dendritic cell based cancer vaccine candidate that targets multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). ImmunoCellular’s double-blind, placebo-controlled, 2:1 randomized Phase

CEQ508 is intended to be used as a treatment for reducing the levels of beta-catenin protein in the epithelial cells of the small and large intestine. In the

AVL-192 is an oral compound that silences the HCV protease (NS3) through irreversible covalent bonding to the target protein. Preclinical data presented by Avila demonstrated that it selectively

As per the agreement, AustarPharma will use its proprietary technologies for developing and manufacturing products for Amerigen to commercialize in the US and other territories. The terms of

Luminex’s xTAG GPP detects hemolytic-uremic syndrome (HUS) causing Shiga-like toxin producing E. coli strain (STEC), besides detecting common disease-causing gastrointestinal pathogens, including viruses, bacteria and parasites, such as

The company plans to recruit around 117 patients in the trial. The primary objective of the trial is to establish the hematologic improvement-erythroid (HI-E) response rate as measured